Novo Nordisk AS’s investigational oral version of its GLP-1 agonist semaglutide is safe in patients with type 2 diabetes at high cardiovascular risk, according to full results from the PIONEER 6 study released at the American Diabetes Association (ADA) on 11 June, which showed a non-significant 21% reduction in major adverse cardiac events (MACE).
Full results of PIONEER 6, topline data from which was released last November, showed the trial met the primary objective...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
